{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:42:19Z","timestamp":1764996139604,"version":"build-2065373602"},"reference-count":51,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.vaccine.2017.12.045","type":"journal-article","created":{"date-parts":[[2017,12,26]],"date-time":"2017-12-26T09:13:35Z","timestamp":1514279615000},"page":"644-652","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Development of an FHbp-CTB holotoxin-like chimera and the elicitation of bactericidal antibodies against serogroup B Neisseria meningitidis"],"prefix":"10.1016","volume":"36","author":[{"given":"Gregory A.","family":"Price","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret C.","family":"Bash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.12.045_b0005","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1586\/14760584.2015.1016915","article-title":"Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen","volume":"14","author":"Seib","year":"2015","journal-title":"Exp Rev Vacc"},{"key":"10.1016\/j.vaccine.2017.12.045_b0010","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4049\/jimmunol.177.1.501","article-title":"The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance","volume":"177","author":"Madico","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.12.045_b0015","doi-asserted-by":"crossref","first-page":"7566","DOI":"10.4049\/jimmunol.176.12.7566","article-title":"Functional significance of factor H binding to Neisseria meningitidis","volume":"176","author":"Schneider","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.12.045_b0020","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1128\/IAI.01071-08","article-title":"Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37","volume":"77","author":"Seib","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.12.045_b0025","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1128\/IAI.72.4.2088-2100.2004","article-title":"Vaccine potential of the Neisseria meningitidis 2086 lipoprotein","volume":"72","author":"Fletcher","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.12.045_b0030","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1084\/jem.20021911","article-title":"Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870","volume":"197","author":"Masignani","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2017.12.045_b0035","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1128\/MMBR.00056-12","article-title":"Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease","volume":"77","author":"McNeil","year":"2013","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.vaccine.2017.12.045_b0040","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1016\/j.vaccine.2010.06.083","article-title":"Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease","volume":"28","author":"Jiang","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.12.045_b0045","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1128\/IAI.00891-10","article-title":"Characterization of diverse subvariants of the meningococcal factor H (fH) binding protein for their ability to bind fH, to mediate serum resistance, and to induce bactericidal antibodies","volume":"79","author":"Seib","year":"2011","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.12.045_b0050","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1016\/j.vaccine.2011.04.092","article-title":"Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States","volume":"29","author":"Wang","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.12.045_b0055","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1080\/00325481.2016.1203238","article-title":"Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba(R))","volume":"128","author":"Gandhi","year":"2016","journal-title":"Postgrad Med"},{"key":"10.1016\/j.vaccine.2017.12.045_b0060","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.2217\/fmb.15.91","article-title":"The multicomponent meningococcal serogroup B vaccine (4CMenB): origin, composition, health impact and unknown aspects","volume":"10","author":"Mameli","year":"2015","journal-title":"Future Microbiol"},{"key":"10.1016\/j.vaccine.2017.12.045_b0065","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1128\/CVI.00474-15","article-title":"Susceptibility of meningococcal strains responsible for two serogroup B outbreaks on U.S. University campuses to serum bactericidal activity elicited by the MenB-4C vaccine","volume":"22","author":"Rossi","year":"2015","journal-title":"Clin Vacc Immunol"},{"key":"10.1016\/j.vaccine.2017.12.045_b0070","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1016\/j.vaccine.2010.12.075","article-title":"Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and neisserial heparin binding antigen","volume":"29","author":"Vu","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.12.045_b0075","first-page":"1","article-title":"Meningococcal serogroup B vaccines: estimating breadth of coverage","author":"Donald","year":"2016","journal-title":"Hum Vacc Immunother"},{"key":"10.1016\/j.vaccine.2017.12.045_b0080","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40265-013-0155-7","article-title":"A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program","volume":"74","author":"O'Ryan","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.vaccine.2017.12.045_b0085","doi-asserted-by":"crossref","first-page":"e0135996","DOI":"10.1371\/journal.pone.0135996","article-title":"A newly-identified polymorphism in rhesus macaque complement factor H modulates binding affinity for meningococcal FHbp","volume":"10","author":"Konar","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.12.045_b0090","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.4049\/jimmunol.1003470","article-title":"A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination","volume":"186","author":"Beernink","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.12.045_b0095","doi-asserted-by":"crossref","first-page":"e01625","DOI":"10.1128\/mBio.01625-14","article-title":"Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH binding","volume":"5","author":"Costa","year":"2014","journal-title":"MBio"},{"key":"10.1016\/j.vaccine.2017.12.045_b0100","doi-asserted-by":"crossref","first-page":"7168","DOI":"10.1016\/j.vaccine.2015.10.135","article-title":"Effect of complement Factor H on anti-FHbp serum bactericidal antibody responses of infant rhesus macaques boosted with a licensed meningococcal serogroup B vaccine","volume":"33","author":"Giuntini","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.12.045_b0105","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/infdis\/jiv081","article-title":"Binding of Complement Factor H (FH) decreases protective anti-FH binding protein antibody responses of infant rhesus macaques immunized with a meningococcal serogroup B vaccine","volume":"212","author":"Granoff","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.12.045_b0110","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.1016\/j.vaccine.2013.08.099","article-title":"Meningococcal factor H-binding protein vaccines with decreased binding to human complement factor H have enhanced immunogenicity in human factor H transgenic mice","volume":"31","author":"Rossi","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.12.045_b0115","doi-asserted-by":"crossref","first-page":"e00842","DOI":"10.1128\/mBio.00842-15","article-title":"Functional analysis of the human antibody response to meningococcal factor H binding protein","volume":"6","author":"Beernink","year":"2015","journal-title":"MBio"},{"key":"10.1016\/j.vaccine.2017.12.045_b0120","doi-asserted-by":"crossref","first-page":"e88907","DOI":"10.1172\/jci.insight.88907","article-title":"Enhanced protective antibody to a mutant meningococcal factor H-binding protein with low-factor H binding","volume":"1","author":"Granoff","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.vaccine.2017.12.045_b0125","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1208\/s12248-016-9979-x","article-title":"The dual role of lipids of the lipoproteins in Trumenba, a self-adjuvanting vaccine against meningococcal Meningitis B disease","volume":"18","author":"Luo","year":"2016","journal-title":"AAPS J"},{"key":"10.1016\/j.vaccine.2017.12.045_b0130","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1586\/14760584.2015.1091732","article-title":"Recombinant bacterial lipoproteins as vaccine candidates","volume":"14","author":"Leng","year":"2015","journal-title":"Exp Rev Vacc"},{"key":"10.1016\/j.vaccine.2017.12.045_b0135","doi-asserted-by":"crossref","first-page":"15602","DOI":"10.1074\/jbc.M113.539510","article-title":"Involvement of Neisseria meningitidis lipoprotein GNA2091 in the assembly of a subset of outer membrane proteins","volume":"289","author":"Bos","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2017.12.045_b0140","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B meningococcus","volume":"103","author":"Giuliani","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2017.12.045_b0145","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.4049\/jimmunol.154.9.4322","article-title":"Mucosal immunization with a bacterial protein antigen genetically coupled to cholera toxin A2\/B subunits","volume":"154","author":"Hajishengallis","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.12.045_b0150","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.1128\/iai.60.11.4915-4924.1992","article-title":"Fusion proteins containing the A2 domain of cholera toxin assemble with B polypeptides of cholera toxin to form immunoreactive and functional holotoxin-like chimeras","volume":"60","author":"Jobling","year":"1992","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.12.045_b0155","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3390\/vaccines3030579","article-title":"Cholera toxin subunit B as adjuvant\u2013an accelerator in protective immunity and a break in autoimmunity","volume":"3","author":"Stratmann","year":"2015","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2017.12.045_b0160","doi-asserted-by":"crossref","first-page":"e42434","DOI":"10.1371\/journal.pone.0042434","article-title":"Evaluation of TcpF-A2-CTB chimera and evidence of additive protective efficacy of immunizing with TcpF and CTB in the suckling mouse model of cholera","volume":"7","author":"Price","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.12.045_b0165","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1006\/jmbi.1995.0456","article-title":"The three-dimensional crystal structure of cholera toxin","volume":"251","author":"Zhang","year":"1995","journal-title":"J Mol Biol"},{"key":"10.1016\/j.vaccine.2017.12.045_b0170","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1128\/IAI.66.10.4755-4761.1998","article-title":"Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with an outer membrane vaccine","volume":"66","author":"Milagres","year":"1998","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.12.045_b0175","doi-asserted-by":"crossref","first-page":"e3356","DOI":"10.1371\/journal.pntd.0003356","article-title":"Immunizing adult female mice with a TcpA-A2-CTB chimera provides a high level of protection for their pups in the infant mouse model of cholera","volume":"8","author":"Price","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2017.12.045_b0180","first-page":"970","article-title":"Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup B, strain 44\/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine","volume":"12","author":"Borrow","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2017.12.045_b0185","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1128\/jcm.11.1.35-40.1980","article-title":"Microtiter ganglioside enzyme-linked immunosorbent assay for vibrio and Escherichia coli heat-labile enterotoxins and antitoxin","volume":"11","author":"Sack","year":"1980","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2017.12.045_b0190","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1086\/528994","article-title":"Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen","volume":"197","author":"Welsch","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.12.045_b0195","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.4049\/jimmunol.148.7.1999","article-title":"Cyclic AMP-independent effects of cholera toxin on B cell activation. II. Binding of ganglioside GM1 induces B cell activation","volume":"148","author":"Francis","year":"1992","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.12.045_b0200","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1073\/pnas.93.1.226","article-title":"Potent immunogenicity of the B subunits of Escherichia coli heat-labile enterotoxin: receptor binding is essential and induces differential modulation of lymphocyte subsets","volume":"93","author":"Nashar","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2017.12.045_b0205","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/infdis\/jit239","article-title":"Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines","volume":"208","author":"Konar","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.12.045_b0210","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.4049\/jimmunol.172.9.5606","article-title":"Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine","volume":"172","author":"Welsch","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.12.045_b0215","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1042\/BCJ20160806","article-title":"Neisseria meningitidis factor H-binding protein bound to monoclonal antibody JAR5: implications for antibody synergy","volume":"473","author":"Malito","year":"2016","journal-title":"Biochem J"},{"key":"10.1016\/j.vaccine.2017.12.045_b0220","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1073\/pnas.1222845110","article-title":"Defining a protective epitope on factor H binding protein, a key meningococcal virulence factor and vaccine antigen","volume":"110","author":"Malito","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2017.12.045_b0225","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1128\/JB.01308-09","article-title":"Expression of factor H binding protein of meningococcus responds to oxygen limitation through a dedicated FNR-regulated promoter","volume":"192","author":"Oriente","year":"2010","journal-title":"J Bacteriol"},{"key":"10.1016\/j.vaccine.2017.12.045_b0230","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1073\/pnas.1521142113","article-title":"Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined","volume":"113","author":"Biagini","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2017.12.045_b0235","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1128\/IAI.02984-14","article-title":"Binding of complement factor H to PorB3 and NspA enhances resistance of Neisseria meningitidis to anti-factor H binding protein bactericidal activity","volume":"83","author":"Giuntini","year":"2015","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.12.045_b0240","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1084\/jem.129.6.1327","article-title":"Human immunity to the meningococcus. II. Development of natural immunity","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2017.12.045_b0245","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2017.12.045_b0250","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/infdis\/172.5.1279","article-title":"Complement-mediated bactericidal activity of human antibodies to poly alpha 2\u2013>8 N-acetylneuraminic acid, the capsular polysaccharide of Neisseria meningitidis serogroup B","volume":"172","author":"Mandrell","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.12.045_b0255","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1128\/iai.40.1.257-264.1983","article-title":"Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide","volume":"40","author":"Zollinger","year":"1983","journal-title":"Infect Immun"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1731798X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1731798X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:24:29Z","timestamp":1759400669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1731798X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0264410X1731798X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.12.045","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of an FHbp-CTB holotoxin-like chimera and the elicitation of bactericidal antibodies against serogroup B Neisseria meningitidis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.12.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}